Here you will find press releases, an image bank and can subscribe to our releases. If you do not find what you are looking for, do not hesitate to contact us.
- Bulletin from Annual General Meeting in InDex Pharmaceuticals Holding AB (publ)06 May 2019 - Regulatory press release
- InDex Pharmaceuticals Holding AB (publ) interim report January – March 201906 May 2019 - Regulatory press release
- InDex Pharmaceuticals provides status update on the patient recruitment in the CONDUCT study11 April 2019 - Regulatory press release
Cobitolimod (Kappaproct, DIMS0150) is a potential new medication for patients with moderate to severe active ulcerative colitis.
Cobitolimod is a first in class treatment that provides a local anti-inflammatory effect which in clinical trials has shown to result in significant improvements of the major clinical symptoms.
Cobitolimod has very limited systemic absorption. This gives the drug a favorable safety profile, in sharp contrast to many approved treatments.Learn more